GSK Bio
NEWS
Blenrep is GSK’s second regulatory approval in four months. GlaxoSmithKline is once again making its mark as an oncology-focused pharmaceutical company.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a COVID-19 vaccine candidate under development by the two companies.
Three months after joining forces to develop an adjuvanted vaccine for COVID-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
“We are pleased the committee recognized the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options,” said Axel Hoos, senior vice president and heat of Oncology R&D for GSK.
It has already administered the first doses of the candidate in healthy human subjects, and the company intends to initiate a Phase II/III trial this coming October.
GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.
Sanofi Pasteur and Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases. The original deal was entered in 2018.
JOBS
IN THE PRESS